Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Giant Viruses | 4 | 2019 | 27 | 1.23 | Why? |
| France | 25 | 2021 | 12074 | 0.96 | Why? |
| Hepatitis E | 4 | 2019 | 319 | 0.95 | Why? |
| Hepatitis C, Chronic | 5 | 2018 | 973 | 0.88 | Why? |
| Azithromycin | 9 | 2021 | 3943 | 0.87 | Why? |
| Hepatitis E virus | 3 | 2019 | 306 | 0.85 | Why? |
| Hydroxychloroquine | 10 | 2021 | 12447 | 0.75 | Why? |
| Amoeba | 2 | 2018 | 22 | 0.74 | Why? |
| Foodborne Diseases | 1 | 2019 | 89 | 0.74 | Why? |
| Mimiviridae | 4 | 2018 | 27 | 0.69 | Why? |
| Amino Acid Substitution | 2 | 2021 | 1706 | 0.66 | Why? |
| Enterovirus | 1 | 2020 | 402 | 0.65 | Why? |
| Hepatitis A | 1 | 2018 | 140 | 0.61 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.59 | Why? |
| Nucleotides | 1 | 2017 | 212 | 0.59 | Why? |
| Hepatitis, Viral, Human | 1 | 2018 | 196 | 0.58 | Why? |
| Virophages | 3 | 2019 | 9 | 0.57 | Why? |
| Genome, Viral | 9 | 2021 | 13157 | 0.57 | Why? |
| Syphilis | 1 | 2018 | 318 | 0.54 | Why? |
| Genotype | 6 | 2021 | 4697 | 0.53 | Why? |
| Amino Acids | 1 | 2017 | 552 | 0.52 | Why? |
| Ribavirin | 2 | 2019 | 1182 | 0.51 | Why? |
| Hepatitis B | 2 | 2018 | 888 | 0.48 | Why? |
| Liver Cirrhosis | 3 | 2019 | 1810 | 0.48 | Why? |
| Orthomyxoviridae | 1 | 2020 | 1168 | 0.46 | Why? |
| Sequence Analysis, RNA | 1 | 2021 | 2290 | 0.46 | Why? |
| Carcinoma, Hepatocellular | 2 | 2019 | 1222 | 0.45 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.45 | Why? |
| Coronavirus | 4 | 2020 | 18339 | 0.42 | Why? |
| Hepatitis B virus | 1 | 2017 | 882 | 0.40 | Why? |
| Liver Neoplasms | 2 | 2019 | 1666 | 0.39 | Why? |
| Viruses | 2 | 2020 | 2238 | 0.38 | Why? |
| Homosexuality, Male | 1 | 2018 | 1158 | 0.37 | Why? |
| Antiviral Agents | 12 | 2021 | 41703 | 0.35 | Why? |
| Viral Load | 8 | 2021 | 15850 | 0.35 | Why? |
| Acanthamoeba | 2 | 2018 | 36 | 0.35 | Why? |
| Eye Diseases | 1 | 2018 | 1150 | 0.33 | Why? |
| DNA Viruses | 3 | 2017 | 184 | 0.33 | Why? |
| Nasopharynx | 8 | 2021 | 10224 | 0.32 | Why? |
| Mutation | 4 | 2021 | 12376 | 0.31 | Why? |
| HIV Infections | 5 | 2018 | 11620 | 0.31 | Why? |
| SARS Virus | 2 | 2020 | 13021 | 0.31 | Why? |
| Opportunistic Infections | 1 | 2012 | 602 | 0.31 | Why? |
| Chiroptera | 1 | 2020 | 3530 | 0.28 | Why? |
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 275 | 0.27 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.27 | Why? |
| Phylogeny | 9 | 2021 | 13341 | 0.27 | Why? |
| Coinfection | 3 | 2020 | 6820 | 0.26 | Why? |
| Drug Synergism | 3 | 2021 | 833 | 0.25 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.25 | Why? |
| HIV-1 | 1 | 2018 | 3365 | 0.25 | Why? |
| Drug Therapy, Combination | 7 | 2021 | 7268 | 0.24 | Why? |
| Interspersed Repetitive Sequences | 2 | 2019 | 29 | 0.24 | Why? |
| Betacoronavirus | 19 | 2020 | 204454 | 0.23 | Why? |
| Hepatitis C | 3 | 2017 | 1514 | 0.22 | Why? |
| Chloroquine | 3 | 2020 | 3152 | 0.21 | Why? |
| Humans | 60 | 2021 | 930598 | 0.21 | Why? |
| Microscopy, Electron | 2 | 2020 | 830 | 0.20 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.20 | Why? |
| Coronavirus Infections | 19 | 2020 | 253789 | 0.19 | Why? |
| Condylomata Acuminata | 1 | 2019 | 62 | 0.19 | Why? |
| Anus Diseases | 1 | 2019 | 55 | 0.19 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 3633 | 0.19 | Why? |
| Pneumonia, Viral | 18 | 2020 | 243684 | 0.19 | Why? |
| HIV Integrase Inhibitors | 2 | 2017 | 173 | 0.19 | Why? |
| DNA, Intergenic | 1 | 2017 | 7 | 0.18 | Why? |
| Blotting, Western | 1 | 2021 | 863 | 0.18 | Why? |
| Airports | 1 | 2021 | 284 | 0.18 | Why? |
| DNA, Viral | 3 | 2017 | 2521 | 0.18 | Why? |
| Teicoplanin | 1 | 2020 | 191 | 0.18 | Why? |
| Microbiological Techniques | 1 | 2020 | 232 | 0.17 | Why? |
| Nucleotide Motifs | 1 | 2017 | 58 | 0.17 | Why? |
| Gene Transfer, Horizontal | 1 | 2017 | 64 | 0.17 | Why? |
| RNA, Transfer | 1 | 2017 | 66 | 0.17 | Why? |
| Acanthamoeba castellanii | 1 | 2017 | 39 | 0.17 | Why? |
| Kidney Transplantation | 2 | 2019 | 5397 | 0.17 | Why? |
| RNA, Viral | 10 | 2021 | 32276 | 0.16 | Why? |
| Remission, Spontaneous | 1 | 2017 | 186 | 0.16 | Why? |
| DNA Virus Infections | 1 | 2017 | 88 | 0.16 | Why? |
| Protein Biosynthesis | 2 | 2018 | 653 | 0.15 | Why? |
| Africa South of the Sahara | 1 | 2021 | 1335 | 0.15 | Why? |
| Brachial Plexus Neuritis | 1 | 2017 | 130 | 0.15 | Why? |
| Evolution, Molecular | 3 | 2018 | 3691 | 0.14 | Why? |
| Polymerase Chain Reaction | 5 | 2021 | 6740 | 0.14 | Why? |
| Virus Diseases | 1 | 2012 | 3779 | 0.14 | Why? |
| Databases, Genetic | 1 | 2021 | 1127 | 0.14 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2021 | 13720 | 0.14 | Why? |
| HIV Seropositivity | 1 | 2017 | 320 | 0.14 | Why? |
| Rhinovirus | 1 | 2020 | 979 | 0.14 | Why? |
| Genes, Viral | 2 | 2017 | 1428 | 0.14 | Why? |
| Drug Combinations | 2 | 2021 | 3852 | 0.13 | Why? |
| Asia | 1 | 2021 | 2399 | 0.13 | Why? |
| Promoter Regions, Genetic | 1 | 2017 | 823 | 0.13 | Why? |
| Nigeria | 1 | 2021 | 2292 | 0.13 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.13 | Why? |
| Adult | 17 | 2021 | 244371 | 0.13 | Why? |
| Infant | 6 | 2021 | 30274 | 0.13 | Why? |
| Hepacivirus | 3 | 2017 | 1509 | 0.13 | Why? |
| Child, Preschool | 7 | 2021 | 36283 | 0.13 | Why? |
| Ships | 1 | 2021 | 1046 | 0.12 | Why? |
| Aged | 16 | 2021 | 215776 | 0.12 | Why? |
| Infant, Newborn | 4 | 2021 | 23105 | 0.12 | Why? |
| Weight Gain | 1 | 2017 | 552 | 0.12 | Why? |
| Virion | 2 | 2017 | 1444 | 0.12 | Why? |
| Male | 22 | 2021 | 367725 | 0.12 | Why? |
| Africa | 1 | 2021 | 2986 | 0.12 | Why? |
| Antimalarials | 2 | 2021 | 2505 | 0.11 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.11 | Why? |
| Imidazoles | 1 | 2017 | 631 | 0.11 | Why? |
| Recombination, Genetic | 1 | 2018 | 1265 | 0.11 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.11 | Why? |
| Papillomavirus Infections | 1 | 2019 | 861 | 0.10 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2020 | 1234 | 0.10 | Why? |
| Turkey | 1 | 2021 | 3937 | 0.10 | Why? |
| Reagent Kits, Diagnostic | 1 | 2021 | 2149 | 0.10 | Why? |
| Protein Conformation | 1 | 2021 | 4386 | 0.10 | Why? |
| Host-Pathogen Interactions | 4 | 2019 | 11041 | 0.10 | Why? |
| Disease Reservoirs | 1 | 2019 | 1672 | 0.10 | Why? |
| Female | 20 | 2021 | 380317 | 0.10 | Why? |
| Whole Genome Sequencing | 1 | 2021 | 3239 | 0.10 | Why? |
| Drug Repositioning | 4 | 2021 | 5683 | 0.10 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.10 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.09 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.09 | Why? |
| Europe | 3 | 2021 | 12702 | 0.09 | Why? |
| Child | 7 | 2021 | 70012 | 0.09 | Why? |
| Influenza A virus | 1 | 2020 | 2234 | 0.09 | Why? |
| Sexual and Gender Minorities | 1 | 2018 | 1019 | 0.09 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.09 | Why? |
| Incidence | 2 | 2020 | 25622 | 0.08 | Why? |
| Disease Outbreaks | 4 | 2020 | 27595 | 0.08 | Why? |
| Models, Molecular | 1 | 2021 | 7616 | 0.08 | Why? |
| Adolescent | 7 | 2021 | 86841 | 0.08 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.08 | Why? |
| Time Factors | 5 | 2020 | 31397 | 0.08 | Why? |
| Prevalence | 2 | 2019 | 25773 | 0.08 | Why? |
| Global Health | 2 | 2021 | 13911 | 0.08 | Why? |
| Pandemics | 18 | 2021 | 389249 | 0.08 | Why? |
| Oxazines | 2 | 2017 | 279 | 0.07 | Why? |
| Anti-HIV Agents | 1 | 2018 | 2209 | 0.07 | Why? |
| Travel | 2 | 2021 | 7220 | 0.07 | Why? |
| Viral Proteins | 2 | 2021 | 7370 | 0.07 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.07 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 11367 | 0.07 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.07 | Why? |
| China | 3 | 2021 | 50654 | 0.07 | Why? |
| Clinical Trials as Topic | 2 | 2021 | 7330 | 0.07 | Why? |
| Liver Transplantation | 1 | 2020 | 2864 | 0.07 | Why? |
| Piperazines | 2 | 2017 | 445 | 0.07 | Why? |
| Interferons | 1 | 2017 | 2885 | 0.07 | Why? |
| Laboratories | 1 | 2017 | 2858 | 0.07 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.06 | Why? |
| Young Adult | 8 | 2021 | 93724 | 0.06 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.06 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.06 | Why? |
| Viral Nonstructural Proteins | 1 | 2021 | 4810 | 0.06 | Why? |
| Seroepidemiologic Studies | 1 | 2019 | 10017 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.06 | Why? |
| Anti-Bacterial Agents | 2 | 2021 | 10083 | 0.06 | Why? |
| Animals | 6 | 2021 | 78931 | 0.06 | Why? |
| Sputum | 2 | 2020 | 1720 | 0.06 | Why? |
| Pyridones | 2 | 2017 | 738 | 0.06 | Why? |
| Postoperative Complications | 1 | 2020 | 5861 | 0.06 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.05 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.05 | Why? |
| Life Cycle Stages | 1 | 2019 | 162 | 0.05 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.05 | Why? |
| Synteny | 1 | 2017 | 38 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2021 | 536 | 0.04 | Why? |
| Lakes | 1 | 2018 | 83 | 0.04 | Why? |
| Carboxy-Lyases | 1 | 2017 | 2 | 0.04 | Why? |
| Brachial Plexus | 1 | 2017 | 28 | 0.04 | Why? |
| Reverse Transcription | 1 | 2021 | 673 | 0.04 | Why? |
| Oceans and Seas | 1 | 2018 | 73 | 0.04 | Why? |
| Amino Acyl-tRNA Synthetases | 1 | 2017 | 14 | 0.04 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.04 | Why? |
| Mink | 1 | 2021 | 399 | 0.04 | Why? |
| Base Composition | 1 | 2017 | 203 | 0.04 | Why? |
| Hepatitis Antibodies | 1 | 2017 | 100 | 0.04 | Why? |
| Succinates | 1 | 2017 | 79 | 0.04 | Why? |
| Cell Culture Techniques | 1 | 2021 | 704 | 0.04 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.04 | Why? |
| Genomics | 2 | 2019 | 3118 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2019 | 9044 | 0.04 | Why? |
| Epstein-Barr Virus Infections | 1 | 2020 | 366 | 0.04 | Why? |
| Water Microbiology | 1 | 2018 | 248 | 0.04 | Why? |
| Cytoplasm | 1 | 2017 | 304 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Molecular Epidemiology | 1 | 2021 | 1638 | 0.04 | Why? |
| Microscopy, Electron, Transmission | 1 | 2017 | 605 | 0.04 | Why? |
| Virology | 1 | 2019 | 489 | 0.04 | Why? |
| Valine | 1 | 2017 | 359 | 0.04 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.03 | Why? |
| Cell Nucleus | 1 | 2017 | 399 | 0.03 | Why? |
| Air Travel | 1 | 2021 | 585 | 0.03 | Why? |
| Biological Evolution | 1 | 2019 | 641 | 0.03 | Why? |
| Nose | 1 | 2020 | 1093 | 0.03 | Why? |
| Vero Cells | 2 | 2020 | 14117 | 0.03 | Why? |
| Drug Interactions | 1 | 2021 | 1653 | 0.03 | Why? |
| Metagenomics | 1 | 2019 | 823 | 0.03 | Why? |
| Host Specificity | 1 | 2018 | 926 | 0.03 | Why? |
| Carbamates | 1 | 2017 | 485 | 0.03 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.03 | Why? |
| Pyrrolidines | 1 | 2017 | 558 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Pharynx | 1 | 2020 | 1544 | 0.03 | Why? |
| History, 21st Century | 1 | 2019 | 1849 | 0.03 | Why? |
| Computational Biology | 2 | 2017 | 4514 | 0.03 | Why? |
| Long QT Syndrome | 1 | 2021 | 1047 | 0.03 | Why? |
| Liver Function Tests | 1 | 2017 | 1325 | 0.03 | Why? |
| Interferon-beta | 1 | 2017 | 979 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2021 | 1956 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2021 | 2643 | 0.02 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.02 | Why? |
| Base Sequence | 1 | 2017 | 3581 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Proteins | 1 | 2017 | 921 | 0.02 | Why? |
| Cities | 1 | 2021 | 4937 | 0.02 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.02 | Why? |
| Drug Evaluation, Preclinical | 1 | 2020 | 3347 | 0.02 | Why? |
| Seasons | 1 | 2020 | 4071 | 0.02 | Why? |
| Virus Replication | 2 | 2020 | 14331 | 0.02 | Why? |
| Immunomodulation | 1 | 2017 | 1472 | 0.02 | Why? |
| Proteome | 1 | 2018 | 1812 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.02 | Why? |
| Workflow | 1 | 2017 | 2373 | 0.02 | Why? |
| Electrocardiography | 1 | 2021 | 3957 | 0.02 | Why? |
| Research | 1 | 2019 | 2115 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Patient Safety | 1 | 2021 | 4885 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Immunoassay | 1 | 2021 | 4485 | 0.02 | Why? |
| Fear | 1 | 2020 | 3607 | 0.02 | Why? |
| Cell Line | 1 | 2020 | 12040 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Emergency Medical Services | 1 | 2020 | 3557 | 0.02 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.02 | Why? |
| India | 1 | 2021 | 11875 | 0.02 | Why? |
| Liver | 1 | 2018 | 4007 | 0.02 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.01 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.01 | Why? |
| Brazil | 1 | 2018 | 12582 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| Immunoglobulin M | 1 | 2017 | 9091 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2017 | 21571 | 0.01 | Why? |